A5026430959- Parathyroid Disorders and Treatments
- Magnesium in Health and Disease
- Pharmacological Effects and Toxicity Studies
- Biomedical Research and Pathophysiology
- Platelet Disorders and Treatments
- Inflammatory Bowel Disease
- Colorectal Cancer Treatments and Studies
- Advanced Breast Cancer Therapies
- Ocular Surface and Contact Lens
- Antiplatelet Therapy and Cardiovascular Diseases
- Nausea and vomiting management
- Microscopic Colitis
- Histone Deacetylase Inhibitors Research
- Renal and Vascular Pathologies
- Dermatology and Skin Diseases
- Melanoma and MAPK Pathways
- Peripheral Artery Disease Management
- Skin Protection and Aging
- Renal Diseases and Glomerulopathies
- melanin and skin pigmentation
- Cancer Mechanisms and Therapy
- Dialysis and Renal Disease Management
- Blood groups and transfusion
- Chronic Kidney Disease and Diabetes
- Gastrointestinal Bleeding Diagnosis and Treatment
East Sussex County Council
2020
Topivert (United Kingdom)
2017-2019
St George's Hospital
2002
St George's, University of London
2002
Chelsea and Westminster Hospital
1996
Disturbances in mineral metabolism play a central role the development of renal bone disease. In 54-wk, randomized, open-label study, 119 hemodialysis patients were enrolled to compare effects sevelamer hydrochloride and calcium carbonate on bone. Biopsy-proven adynamic disease was most frequent abnormality at baseline (59%). Serum phosphorus, calcium, intact parathyroid hormone well controlled both groups, although consistently lower higher among who randomly assigned sevelamer. Compared...
Thrombocytopenia may be associated with increased bleeding risk impacting timing and outcome of invasive procedures in patients chronic liver disease (CLD). Lusutrombopag, a small‐molecule, thrombopoietin (TPO) receptor agonist, was evaluated as treatment to raise platelet counts (PCs) thrombocytopenia CLD undergoing procedures. L‐PLUS 2 global, phase 3, randomized, double‐blind, placebo‐controlled study. Adults baseline PCs < 50 × 10 9 /L were randomized receive once‐daily lusutrombopag...
Atherosclerotic renovascular disease (ARVD) is commonly associated with renal failure. It now recognized that intrarenal damage, (ischaemic or atherosclerotic nephropathy) a major contributor to the impairment in these patients. In this study impact of histological changes upon functional outcome was investigated patients nephropathy.The Hope Hospital biopsy database (1985-1998) interrogated for histology compatible nephropathy. Case-note review enabled assessment several clinical parameters...
Background and objectives: Sevelamer carbonate is an improved, buffered form of sevelamer hydrochloride developed for the treatment hyperphosphatemia in patients with chronic kidney disease. This study investigated ability to control serum phosphorous hyperphosphatemic who had disease were not on dialysis. Design, setting, participants, & measurements: was open-label, dosage-titration study. Patients phosphorus ≥5.5 mg/dl enrolled (<i>n</i> = 46). administered 8 wk. supplemented native...
The T594M polymorphism of the epithelial sodium channel is found in approximately 5% people African origin and significantly associated with high blood pressure. Although could increase renal absorption through affected channels, it not known whether this causes hypertension. Amiloride specifically inhibits overactive channels effectively controls pressure Liddle's syndrome, which hypertension caused by separate mutations. aim study was to determine amiloride effective lowering individuals...
Background. Inadequate phosphorus control is associated with increased morbidity and mortality in patients CKD stage 5. Although phosphate binders are often used on peritoneal dialysis (PD), no large randomized controlled studies evaluating their use solely this population have previously been reported.
To evaluate the safety and efficacy of topical TOP1630, a novel nonsystemic kinase inhibitor, in dry eye disease (DED).A randomized, double-masked, parallel-group trial 0.1% TOP1630 ophthalmic solution TID or placebo (vehicle without active drug) was conducted DED subjects (n=61). Key eligibility criteria consistent with enrolling moderate to severe population included >6 months history; OSDI© score ≥18; Schirmer's test ≤10 ≥1 mm/5 minutes; tear film break-up time >1 <7 seconds; exacerbation...
CD4 lymphocytes mediate disease expression in both human immunodeficiency virus (HIV) infection and inflammatory bowel (IBD). Analysis of the clinical course IBD HIV-seropositive individuals may elucidate aspects role pathogenesis these conditions.A retrospective case series study.Diagnostic coding for pharmacy records 5-aminosalicylic acid compounds rectal steroid preparations were examined all subjects attending Chelsea Westminster Hospitals between January 1988 December 1993. Eight with a...
To evaluate the efficacy of orvepitant (10 or 30 mg given once daily, orally for 4 weeks), a neurokinin-1 receptor antagonist, compared with placebo in reducing intensity epidermal growth factor inhibitor (EGFRI)-induced intense pruritus.Randomised, double-blind, placebo-controlled clinical trial.15 hospitals Italy and five UK.44 patients aged ≥18 years receiving an EGFRI histologically confirmed malignant solid tumour experiencing moderate pruritus after treatment.30 10 tablets daily weeks...
TOP1288 is a topically acting, narrow spectrum kinase inhibitor that selectively targets key kinases (p38apha, Src family kinases, and Syk) involved in inflammatory signalling cells of the innate adaptive immune systems. has minimal systemic absorption, free from or local toxicities potential to provide safe efficacious, chronic dosing treatment for bowel disease (IBD) as demonstrated by prior study with rectal formulation.1,2 Combining an innovative trial design bespoke assays target...
Background: TOP1288 a novel narrow spectrum kinase inhibitor (NSKI), selectively targets key kinases fundamental to inflammatory cell signalling in innate and adaptive immune responses: p38-alpha MAP kinase, Src family (Src Lck) Syk. Through synergistic effects on these is potent of the cascade offers therapeutic potential ulcerative colitis Crohn's disease with minimal systemic absorption which could provide significant safety advantage over current therapies. In healthy subjects (evaluated...